US Senate bill aimed at streamlining combination product regulation
This article was originally published in Clinica
Executive Summary
A new US Senate bill, the Combination Product Regulatory Fairness Act of 2015, is intended to streamline device/drug combination registrations at the FDA by letting the agency rely on prior PMAs and approved drug findings to support new product approvals, among other reforms.